Acute inflammatory and anabolic systemic responses to peak and constant-work-rate exercise bout in hospitalized patients with COPD.
OBJECTIVE
To explore the acute systemic inflammatory and anabolic effects of cycling in hospital admitted patients with chronic obstructive pulmonary disease (COPD) and in patients with clinically stable disease.


METHODS
Cross-sectional comparative study.


METHODS
University Hospital Gasthuisberg, a tertiary care setting.


METHODS
16 patients with clinically stable COPD (no acute exacerbation in the past 12 weeks; median age: 73 years (IQR: 60 to 75); median forced expiratory volume in the first second (FEV1): 45% predicted (IQR: 33 to 58)) and 14 patients who were admitted to a hospital due to an acute exacerbation of COPD (median age: 65 years (IQR: 59 to 74); median FEV1 on day 8 of hospital stay: 41% predicted (IQR: 33 to 54)).


METHODS
None.


RESULTS
Circulating levels of C reactive protein, interleukin 6, interleukin 8 and insulin-like growth factor I were determined before, at the end and 2 and 30 minutes after a symptom-limited peak cycling test and before, at the end and 2 and 30 minutes after a symptom-limited constant-work-rate cycling test at 70% of the peak load. Non-significant changes in the circulating markers of inflammation and anabolism were found during or up to 30 minutes after ceasing the peak or constant-work-rate cycling exercise tests. The systemic responses of the hospitalized patients with COPD did not differ from those with clinically stable disease.


CONCLUSIONS
High-intensity cycling exercises did not increase the circulating levels of inflammatory markers in patients with chronic obstructive pulmonary disease, irrespective of their clinical stability.
Spruit
Martijn A
MA
Respiratory Rehabilitation and Respiratory Division, University Hospital Gasthuisberg, Leuven, Belgium.
Troosters
Thierry
T
Gosselink
Rik
R
Kasran
Ahmad
A
Decramer
Marc
M
D000368:Aged; D001530:Belgium; D002097:C-Reactive Protein / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D003430:Cross-Sectional Studies; D017079:Exercise Tolerance / Q000276:immunology* / Q000502:physiology; D005260:Female; D006785:Hospitals, University; D006801:Humans; D007297:Inpatients; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D015850:Interleukin-6 / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D016209:Interleukin-8 / Q000032:analysis / Q000276:immunology / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D029424:Pulmonary Disease, Chronic Obstructive / Q000276:immunology*
C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D015850:Interleukin-6; D016209:Interleukin-8; D002097:C-Reactive Protein